Receive funding for your R&D Projects!
Your partner for subsidy advice
Your partner for subsidy advice
Inhibitors for use in human therapy Invention
The invention provides a new class of nucleosides
…
Free Flow Electrophoresis (FFE) systems allow researchers to reduce the complexity of samples and enrich low abundant proteins with very high reproducibility….
Invention
Scientists at the University of Münster, Germany, have isolated and characterized a novel substance class from Cocoa. CocoaHeal is capable of…
Professor Ritter and his co-workers from the Division of Virology, University Hospital of the RWTH Aachen, created a new recombinant Epstein-Barr Virus (EBV)
which has lost the ability to enter the state of latent persistency after infecting host cells. The mutant virus only causes a self-limited infection and is unable to immortalize B-lymphocytes following Infection. Having lost the oncogenic potential of wild type EBV it fulfils the prerequisite for a live vaccine.
The inventors generated a mutant virus allowing expression of lytic genes, but preventing the expression of EBV encoded genes essential for the establishment of
viral latency. Mutant virus infected B-lymphocytes died after the productive phase….
Protective natural products from sessile animals as highly efficient bioactive antifouling agents.
BIANTS are synthesised bastadins, modified depsipeptides,…
Purinergic receptors have been in the focus of drug discovery for many years. This invention provides nonnucleotide
agonists of the P2Y11-receptor. The…